Skip to main content

Chronic Kidney Disease, Diabetes Mellitus, Hypertension and Medication Possession Ratio for ACEI/ARB Therapy

CBE ID
0550
1.4 Project
Renal Consensus Standards Endorsement Maintenance
Endorsed
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
E&M Cycle
Full Year 2011
Is Under Review
No
1.3 Measure Description

Medication Possession Ratio (MPR) for ACEI/ARB therapy for individuals with Chronic Kidney Disease (CKD) and/or diabetes mellitus and hypertension.

    • 1.14 Numerator

      The sum of the days supply that fall within the measurement window for an ACEI/ARB fill for each patient in the denominator.

      Time window: Anytime during the measurement period (12 months)

      MPR Numerator:
      1. New users: For patients with no prescriptions in the 180 days prior to the measurement period, sum of:

      Days’ supply of all medications from the first prescription until the end of the measurement period.

      **Remove the days’ supply that extend past the end of the measurement period.

      2. Continuous users: For patients with 1 or more prescriptions in the 180 days prior to the measurement period, sum of:

      Days’ supply of all medications in the measurement period

      **Remove the days supply that extends past the end of the measurement period and add days supply from the previous period that apply to the current period.

    • 1.15 Denominator

      Beneficiaries with CKD stages 1-4 and/or diabetes mellitus and hypertension (HTN) identified during the measurement period with at least one Part D claim for an ACEI/ARB.

      Time window: Anytime during the measurement period (12 consecutive months)

      MPR Denominator:
      1. New users: Number of days from the first prescription to the end of measurement period.
      2. Continuous users: Number of days from the beginning to the end of the measurement period

    • Exclusions

      Patients who died during the measurement period.
      Patients who are actively enrolled in multiple plans concurrently as of the end of the measurement period.
      Patients who have had a kidney transplant during the measurement period.
      Patients who have ESRD.
      Patients with a diagnosis of polycystic ovaries who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.
      Patients with a diagnosis of gestational diabetes or steroid-induced diabetes who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Renal Consensus Standards Endorsement Maintenance 2011
      Initial Endorsement
      Last Updated
      Removal Date